

Login

User name: email address

Select role: Pathologist/Editor (Admin)

PSW:12345678 (for all editor by default)

Jane.Houldsworth@mountsinai.org

.....

Pathologist/Editor



Login

- Editor end

Welcome Jane:

Variant Curation Viewer

Select
'Tumor type'

Please select tumor type

Genes

Mutations

NARRATIVE

MUTATION INFORMATION

Interface and steps of viewer:

1. Select 'Tumor type'
2. Select 'Gene'
3. Select 'Mutation'
4. Click 'NARRATIVE' / MUTATION INFORMATION'

Variant Curation Viewer

LOG OUT

NSCLC

PTEN

loss-of-function

Click
'Narrative'

NARRATIVE

MUTATION INFORMATION

Click this button
to see the
annotated
informationClick 'Log
out' to quit
the tool**NSCLC/PTEN/loss-of-function mutation**

PTEN is mutated in 4-8% of non-small cell lung cancers [PMID: 20018398, PMID: 9598803, PMID: 20881644]. PTEN encodes a tumor suppressor that works as a phosphatase to convert PIP3 to PIP2 at the cell membrane [PMID: 18767981]. The loss-of-function mutations of PTEN result in PIP3 accumulation and AKT/mTOR signaling constitutive activation [PMID: 12040186].

NSCLC/PTEN/LOF mutation/Buparlisib (BKM120) (score R)

Buparlisib is a small molecule pan-PI3K inhibitor of p110 $\alpha/\beta/\delta/\gamma$ [PMID: 24900266]. A phase II clinical trial evaluating buparlisib in pretreated metastatic NSCLC displaying PI3K pathway activation showed no significant improved PFS [PMID: 26098748].

EDIT

Click 'EDIT'
to comment
variant

NSCLC/PTEN/loss-of-function mutation

PTEN is mutated in 4-8% of non-small cell lung cancers [PMID: 20018398, PMID: 9598803, PMID: 20881644]. PTEN encodes a tumor suppressor that works as a phosphatase to convert PIP3 to PIP2 at the cell membrane [PMID: 18767981]. The loss-of-function mutations of PTEN result in PIP3 accumulation and AKT/mTOR signaling constitutive activation [PMID: 12040186].

NSCLC/PTEN/LOF mutation/Buparlisib (BKM120) (score R)

Buparlisib is a small molecule pan-PI3K inhibitor of p110 α /β/δ/γ [PMID: 24900266]. A phase II clinical trial evaluating buparlisib in pretreated metastatic NSCLC displaying PI3K pathway activation showed no significant improved PFS [PMID: 26098748].

1: NSCLC/PTEN/loss-of-function mutation

PTEN is mutated in 4-8% of non-small cell lung cancers [PMID: 20018398, PMID: 9598803, PMID: 20881644]. PTEN encodes a tumor suppressor that works as a phosphatase to convert PIP3 to PIP2 at the cell membrane [PMID: 18767981]. The loss-of-function mutations of PTEN result in PIP3 accumulation and AKT/mTOR signaling constitutive activation [PMID: 12040186].

- Jane.Houldsworth@mountsinai.org: 2017-09-16 20:28:30: Testing NSCLC

save

Steps of viewer end editing,click 'Save'

Make comments and click 'save'

2: NSCLC/PTEN/LOF mutation/Buparlisib (BKM120) (score R)

Buparlisib is a small molecule pan-PI3K inhibitor of p110 α /β/δ/γ [PMID: 24900266]. A phase II clinical trial evaluating buparlisib in pretreated metastatic NSCLC displaying PI3K pathway activation showed no significant improved PFS [PMID: 26098748].

- Jane.Houldsworth@mountsinai.org: 2017-09-16 20:29:36: 2nd testing

Show 10 entries

Search:

narrative	ver_name	date_admin
Browse	version2	2017-09-17 19:42:21
Browse		2017-09-17 19:44:16

Showing 1

Previous 1 Next

EDIT

Click 'Browse' to see different versions made by Admin (next slide)

Version made by Admin and displayed in Editor end

Modification of the narrative

MTC/RET/A883F

[Editing the comments from ADMIN 1st...][Editing the comments from ADMIN END 1st version of 2nd run]RET c.2647_2648GC>TT is a missense mutation in exon 15 (codon 883). This mutation yields an alanine to phenylalanine change (A883F) in the intracellular tyrosine kinase domain. This mutation is causative for multiple endocrine neoplasia type 2b (MEN2B) [PMID: 16849421]. RET A883F occurs in 2-3% of MEN2B cases[PMID: 23059849].

MTC/RET/M918T/Sorafenib (score 2)

Sorafenib is a small molecule multi-targeted kinase inhibitor of Raf-1, BRAF, VEGFR2, KIT and RET [PMID: 15466206]. Although there is no specific RET inhibitor available and no FDA approved for treatment of MTC, some multikinase inhibitors including sorafenib are recommended for treatment of patients with MTC if clinical trials, vandetanib, or cabozantinib are not available or appropriate, or if the patient progresses on vandetanib or cabozantinib [NCCN Guidelines Version 2. 2017 Thyroid Carcinoma].

MTC/RET/M918T/Sunitinib (score 2)

Sunitinib is a small molecule multi-targeted RTK inhibitor of VEGFR2, KIT, PDGFR β and RET [PMID: 12646019]. Although there is no specific RET inhibitor available and no FDA approved for treatment of MTC, some multikinase inhibitors including sunitinib are recommended for treatment of patients with MTC if clinical trials, vandetanib, or cabozantinib are not available or appropriate, or if the patient progresses on vandetanib or cabozantinib [NCCN Guidelines Version 2. 2017 Thyroid Carcinoma].

MTC/RET/M918T/Vandetanib (score 2)

Vandetanib is a small molecule multi-targeted kinase inhibitor of VEGFR2, EGFR and RET [PMID: 12183421]. Vandetanib is recommended for treatment of medullary thyroid cancer [NCCN Guidelines Version 2. 2017 Thyroid Carcinoma].

Show 10 entries		
Search: <input type="text"/>		
narrative	ver_name	date_admin
Modify	version2	2017-09-17 19:42:21
Current Version	version1	2017-09-17 19:44:16
Showing 1 to 2 of 2 entries (filtered from 14 total entries)		
Previous 1 Next		

paragraph 1:

- jinlian.wang@mssm.edu: 2017-09-15 21:43:54: Testing... MTC
- jinlian.wang@mssm.edu: 2017-09-17 19:34:44: 2nd testing... MTC
- jinlian.wang@mssm.edu: 2017-09-17 19:34:55: 2nd testing... MTC
- jinlian.wang@mssm.edu: 2017-09-17 19:35:47: continue testing... MTC

paragraph 2:

- ADMIN END

Admin End

NSCLC

PIK3R1

D560N

NARRATIVE

MUTATION INFORMATION

1: **NSCLC/PIK3R1/D560N**

PIK3R1 encodes the regulatory subunit (p85) of PI3K. Its mutations were found in 1.7% of NSCLCs [PMID: 27158780]. *PIK3R1* c.1678G>A is a missense mutation in the iSH2 domain and yields an aspartic acid to asparagine change (D560N). The PIK3R1 D560N mutation accounts for about 5% of all PIK3R1 mutations in lung cancers [PMID: 27158780]. PIK3R1 D560N mutation likely results in loss of inhibition of the PI3K catalytic subunit and aberrant activation of downstream signaling pathways such as AKT/mTOR pathway [PMID: 20713702, PMID: 9450999, PMID: 11606375, PMID: 15932879, PMID: 17626883, PMID: 18079394, PMID: 19962665, PMID: 21984976].

- jinlian.wang@mssm.edu: 2017-09-17 19:16:16: last testing....

2: **NSCLC/PIK3R1/D560N/Buparlisib(BKM120) (score R)**

Buparlisib is a small molecule pan-PI3K inhibitor of p110 α /β/δ/γ [PMID: 24900266]. A phase II clinical trial evaluating buparlisib pretreated metastatic NSCLC displaying PI3K pathway activation showed no significant improved PFS [PMID: 26098748].

- jinlian.wang@mssm.edu: 2017-09-17 19:16:26: Color code works now

Show	10	entries	Search:	
narrative		ver_name		
		First Version		

Click 'First Version' to name the version

Admin edit narrative

- jinlian.wang@mssm.edu: 2017-09-17 19:16:16: last testing....

2: NSCLC/PIK3R1/D560N/Buparlisib(BKM120) (score R)

Buparlisib is a small molecule pan-PI3K inhibitor of p110 α / β / δ / γ [PMID: 24900266]. A phase II clinical trial evaluating buparlisibin pretreated metastatic NSCLC displaying PI3K pathway activation showed no significant improved PFS [PMID: 26098748].

- jinlian.wang@mssm.edu: 2017-09-17 19:16:16: last testing....

Edit the
narrative
highlighted
yellow

Modify the narrative

NSCLC/PIK3R1/D560N

PIK3R1 encodes the regulatory subunit (p85) of PI3K. Its mutations were found in 1.7% of NSCLCs [PMID: 27158780]. *PIK3R1* c.1678G>A is a missense mutation in the iSH2 domain and yields an aspartic acid to asparagine change (D560N). The PIK3R1 D560N mutation accounts for about 5% of all PIK3R1 mutations in lung cancers [PMID: 27158780]. PIK3R1 D560N mutation likely results in loss of inhibition of the PI3K catalytic subunit and aberrant activation of downstream signaling pathways such as AKT/mTOR pathway [PMID: 20713702, PMID: 9450999, PMID: 11606375, PMID: 15932879, PMID: 17626883, PMID: 18079394, PMID: 19962665, PMID: 21984976].

NSCLC/PIK3R1/D560N/Buparlisib(BKM120) (score R)

Buparlisib is a small molecule pan-PI3K inhibitor of p110 α / β / δ / γ [PMID: 24900266]. A phase II clinical trial evaluating buparlisibin pretreated metastatic NSCLC displaying PI3K pathway activation showed no significant improved PFS [PMID: 26098748].

paragraph 1:

- jinlian.wang@mssm.edu: 2017-09-17 19:16:16: last testing....

paragraph 2:

- jinlian.wang@mssm.edu: 2017-09-17 19:16:26: Color code works now

Show	10	entries
Search: <input type="text"/>		
narrative	ver_name	date_admin
Current Version		
Showing 0 to 0 of 0 entries (filtered from 10 total entries)		
Previous Next		

Version
working
on

ALL COMMENTS SAVE NEW VERSION

Save any
changes
to current
version